India [October 07, 2025] – Terumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, announced the launch of FineCross™ M3 Coronary Micro-Guide Catheter in India.
The latest-generation catheter enhances percutaneous coronary intervention (PCI) procedures by delivering superior crossability, guidewire support, and navigability in complex coronary lesions.
Built on Terumo’s trusted global expertise, FineCross™ M3 empowers physicians to perform safer and more efficient interventions, improving outcomes for patients with challenging coronary anatomies.
Addressing the Growing Burden of CADWith coronary artery disease (CAD) continuing to be the leading cause of death in India, and a rising number of patients presenting with complex lesions, there is an urgent need for advanced interventional tools.
FineCross™ M3 is designed to help cardiologists perform more predictable, efficient, and safer procedures, improving both clinical outcomes and procedural confidence.
Leadership Perspective
Mr. Shishir Agarwal, President and Managing Director, Terumo India, said:
“Innovation at Terumo India is always guided by enabling physicians to deliver the best possible care to patients. With the launch of FineCross™ M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects our commitment to strengthening cardiovascular care and our promise of ‘Unwavering Commitment to Patients’.”
Advanced Design for Complex InterventionsFineCross™ M3 integrates Terumo’s engineering excellence with enhanced design features to address real-world PCI challenges.
Key features include:
- 1.7 Fr tapered distal tip for superior lesion crossability
- 15 cm floppy distal segment for exceptional trackability in tortuous vessels
- Tapered stainless-steel braided shaft for improved pushability and control
- Next-generation hydrophilic coating for enhanced lubrication and durability
- PTFE inner layer with radiopaque marker for smooth delivery and precise visualization
Mr. Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India, added:
“FineCross™ M3 represents more than a product launch—it reflects our continued focus on advancing cardiovascular care in India. Through globally trusted innovations, we aim to empower physicians to deliver better patient outcomes and create meaningful impact where it matters most.”
Strengthening Interventional PortfolioThe launch of FineCross™ M3 further strengthens Terumo India’s growing portfolio of advanced interventional solutions, reinforcing its role in shaping the future of cardiovascular care in India.
About Terumo India Private Limited
Terumo India is a rapidly growing medical devices company dedicated to advancing access to high-quality cardiac, vascular, and other medical devices for patients and healthcare practitioners in India. As part of Terumo Corporation, headquartered in Tokyo, Japan, Terumo India continues its mission of ‘Contributing to Society through Healthcare.’
Founded in 2013 and headquartered in Gurgaon, NCR Delhi, Terumo India has impacted over 100,000 lives. The company is four times Great Place to Work® certified and has been recognized among India’s Top 15 Workplaces™ in Pharmaceuticals, Healthcare, and Biotech.
Terumo India runs several training and development programs in collaboration with customers and academic partners to support India’s evolving healthcare ecosystem.
For more information, visit: https://terumoindia.com/
About Terumo
Terumo (TSE: 4543) is a global medical innovation company committed to improving patient lives through advanced healthcare solutions. Founded in Tokyo in 1921, Terumo operates in more than 160 countries and regions.
Guided by its mission of “Contributing to Society through Healthcare,” Terumo continues to deliver value to patients, healthcare professionals, and society.
For more information, visit: https://www.terumo.com/
